NLRP3 and COVID-19: Taken together, our results demonstrated that specific inhibition of the NLRP3 inflammasome suppresses SARS-CoV-2 induced immune overactivation in the lungs and alleviates COVID-19 like immunopathology, and that targeting the NLRP3 inflammasome might be a potential immune intervention of severe COVID-19 disease.